Data layers Raw facts Calculated Model prediction AI interpretation

Cross-Market Price Comparison

Other Listed Market Shanghai (SSE) — 百奥赛图
Other Market Stock Code688796
H-Share Offer PriceHK$ 25.22
Other Market PriceLoading...
Reference Exchange RateLoading...
H-Share Offer Price Premium/Discount vs Other MarketLoading...

Company Overview

Stock NameBiocytogen-B
Stock Code02315
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們是生物製藥及臨床前研究服務創收公司,業務模式包括藥物開發業務及臨床前研究服務。藥物開發業務包括腫瘤學和自身免疫性疾病治療的研發及抗體開發業務;臨床前研究服務包括基因編輯、臨床前藥理藥效評估及模式動物銷售。
Listing Date2022-09-01
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)北京市大興區大興生物醫藥產業基地寶參南街12號院
Business Address (Hong Kong)香港灣仔皇后大道東248號大新金融中心40樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.biocytogen.com.cn
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 25.22 / shares
Offer Price RangeFinal offer price only, no range
Lot Size500 shares
Entry ThresholdHK$ 12,610
Par ValueRMB 1.0 / shares
Offer Period2022-08-19 to 2022-08-24
Global Offering Shares21,758,500 shares
HK Public Offer Shares (Initial)2,176,000 shares (10.0%)
Public Offer Lots (Initial)4,352lots (Pool A2,176lots,Pool B2,176lots)
International Placing Shares (Initial)19,582,500 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO396,688,420 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share71.1%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 548,749,370

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 500 HK$ 12,610
2 lots 1,000 HK$ 25,220
3 lots 1,500 HK$ 37,830
4 lots 2,000 HK$ 50,440
5 lots 2,500 HK$ 63,050
6 lots 3,000 HK$ 75,660
7 lots 3,500 HK$ 88,270
8 lots 4,000 HK$ 100,880
9 lots 4,500 HK$ 113,490
10 lots 5,000 HK$ 126,100
12 lots 6,000 HK$ 151,320
14 lots 7,000 HK$ 176,540
16 lots 8,000 HK$ 201,760
18 lots 9,000 HK$ 226,980
20 lots 10,000 HK$ 252,200
30 lots 15,000 HK$ 378,300
40 lots 20,000 HK$ 504,400
50 lots 25,000 HK$ 630,500
60 lots 30,000 HK$ 756,600
70 lots 35,000 HK$ 882,700
80 lots 40,000 HK$ 1,008,800
90 lots 45,000 HK$ 1,134,900
100 lots 50,000 HK$ 1,261,000
120 lots 60,000 HK$ 1,513,200
140 lots 70,000 HK$ 1,765,400
160 lots 80,000 HK$ 2,017,600
200 lots 100,000 HK$ 2,522,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
400 lots 200,000 HK$ 5,044,000
600 lots 300,000 HK$ 7,566,000
1,200 lots 600,000 HK$ 15,132,000
1,400 lots 700,000 HK$ 17,654,000
2,176 lots 1,088,000 HK$ 27,439,360

Stock Connect Inclusion Analysis

HK Market Cap HK$ 5.55B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)HK$ 10,004,481,952
H-Share Market Cap (at Offer Price)HK$ 2,725,573,822
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不適用(公司處於虧損狀態)
Profit/Loss Status2021年虧損人民幣545.6百萬元
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 20202021
Revenue 253,542354,555
Cost of sales -86,549-107,115
Gross profit 166,993247,440
Other income and gains, net 27,95935,381
Selling and distribution expenses -31,656-42,032
Administrative expenses -245,416-188,120
Operating profit -358,426-505,816
Net finance costs -22,537-39,425
Share of associates and JVs 87-402
Profit before tax -476,691-545,643
Income tax expense 00
Profit for the year -476,691-545,643
Profit attributable to owners -428,091-545,576
Balance Sheet
Item 202020212022-04
Cash and cash equivalents 750,044466,445
Trade and bills receivables 67,226103,089
Inventories 7,98015,140
Total current assets 1,147,638874,238
Total assets 2,326,5182,302,783
Total current liabilities 328,465446,559
Total liabilities 868,2771,050,812
Total equity 1,458,2411,251,971
Equity attributable to owners 1,453,4111,247,208
Interest-bearing borrowings 80,91889,799114,055
Cash Flow Statement
Item 202020212022-04
Net cash from operating activities -225,313-365,778
Net cash from investing activities -188,180-84,131
Net cash from financing activities 868,442219,440
Net increase in cash 454,949-230,469
Depreciation of PP&E 42,493126,48126,534
Amortisation of intangible assets 8741,616303
Purchase of PP&E -296,420-198,668-87,568
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 26.0
First Day OpenHK$ 26.3
First Day Change3.09%
First Day Volume2302000.0
First Day Turnover61043900.0
Use of Proceeds
1、約329.8百萬港元(即所得款項凈額約70%)用于為我們核心產品的進一步臨床研發提供資金; 2、約70.7百萬港元(即所得款項凈額約15%)用于根據我們的千鼠萬抗計劃為抗體藥物發現及開發提供資金; 3、約47.1百萬港元(即所得款項凈額約10%)用于我們其他管線產品的臨床前及臨床開發; 4、約23.6百萬港元(即所得款項凈額約5%)將用作營運資金及其他一般公司用途。

Underwriting Syndicate

Joint Sponsors (2)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 中国国际金融香港证券有限公司 CE AEN894
Overall Coordinators (4)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 中国国际金融香港证券有限公司 CE AEN894 招银国际融资有限公司 CE AVM940 CLSA LIMITED CE AAB893
Joint Bookrunners (8)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 中国国际金融香港证券有限公司 CE AEN894 招银国际融资有限公司 CE AVM940 CLSA LIMITED CE AAB893 交银国际证券有限公司 CE APJ121 富途证券国际(香港)有限公司 CE AZT137 VALUABLE CAPITAL LIMITED CE AUL711 海通国际证券有限公司 CE AAF806
Joint Lead Managers (8)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 中国国际金融香港证券有限公司 CE AEN894 招银国际融资有限公司 CE AVM940 CLSA LIMITED CE AAB893 交银国际证券有限公司 CE APJ121 富途证券国际(香港)有限公司 CE AZT137 VALUABLE CAPITAL LIMITED CE AUL711 海通国际证券有限公司 CE AAF806

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 QuantumPharm Inc. 76,820,120 HKD — 14.00% — 6 months 2023-03-01
2 北京兴星股权投资合伙企业(有限合伙) 39,191,880 HKD — 7.14% — 6 months 2023-03-01
3 荣昌生物制药(烟台)股份有限公司 78,383,760 HKD — 14.28% — 6 months 2023-03-01
4 三金国际股份有限公司 78,383,760 HKD — 14.28% — 6 months 2023-03-01
5 维科(香港)经贸有限公司 117,588,250 HKD — 21.43% — 6 months 2023-03-01

Directors & Management

PositionChinese nameEnglish Name
Chairman沈月雷—
Company Secretary王永亮、區慧晶—
No director data available.

Major Shareholders

Major Shareholders & Holdings緊隨全球發售完成後(假設超額配股權未獲行使),主要股東包括:沈博士持股約6.7%;倪博士持股約7.3%;國投上海持股約10.6%;國投深圳持股約4.8%;招銀相關基金合共持股約12.1%;星赫持股約6.6%;百奧維達持股約5.1%;中國人壽持股約5.9%。沈博士與倪博士為配偶及一致行動協議訂約方。
About this page

This page shows Biocytogen-B (02315) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect